Management  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
anticoagulation  ||| S:14 E:30 ||| NN
and  ||| S:30 E:34 ||| CC
antiplatelet  ||| S:34 E:47 ||| JJ
therapy  ||| S:47 E:55 ||| NN
in  ||| S:55 E:58 ||| IN
patients  ||| S:58 E:67 ||| NNS
with  ||| S:67 E:72 ||| IN
left  ||| S:72 E:77 ||| VBN
ventricular  ||| S:77 E:89 ||| RB
assist  ||| S:89 E:96 ||| VB
devices  ||| S:96 E:104 ||| NNS
Left  ||| S:104 E:109 ||| VBD
ventricular  ||| S:109 E:121 ||| RB
assist  ||| S:121 E:128 ||| VB
devices  ||| S:128 E:136 ||| NNS
( ||| S:136 E:137 ||| -LRB-
LVADs ||| S:137 E:142 ||| NNP
)  ||| S:142 E:144 ||| -RRB-
have  ||| S:144 E:149 ||| VBP
increased  ||| S:149 E:159 ||| VBN
the  ||| S:159 E:163 ||| DT
survival  ||| S:163 E:172 ||| NN
of  ||| S:172 E:175 ||| IN
patients  ||| S:175 E:184 ||| NNS
with  ||| S:184 E:189 ||| IN
advanced  ||| S:189 E:198 ||| JJ
heart  ||| S:198 E:204 ||| NN
failure  ||| S:204 E:212 ||| NN
fourfold ||| S:212 E:220 ||| NN
.  ||| S:220 E:222 ||| .
Despite  ||| S:222 E:230 ||| IN
these  ||| S:230 E:236 ||| DT
advances ||| S:236 E:244 ||| NNS
,  ||| S:244 E:246 ||| ,
significant  ||| S:246 E:258 ||| JJ
bleeding  ||| S:258 E:267 ||| NN
and  ||| S:267 E:271 ||| CC
thrombotic  ||| S:271 E:282 ||| JJ
complications  ||| S:282 E:296 ||| NNS
occur ||| S:296 E:301 ||| VBP
.  ||| S:301 E:303 ||| .
Hemorrhage  ||| S:303 E:314 ||| RB
requiring  ||| S:314 E:324 ||| VBG
surgery  ||| S:324 E:332 ||| NN
has  ||| S:332 E:336 ||| VBZ
been  ||| S:336 E:341 ||| VBN
reported  ||| S:341 E:350 ||| VBN
in  ||| S:350 E:353 ||| IN
up  ||| S:353 E:356 ||| RB
to  ||| S:356 E:359 ||| TO
30 ||| S:359 E:361 ||| CD
%  ||| S:361 E:363 ||| NN
of  ||| S:363 E:366 ||| IN
adults  ||| S:366 E:373 ||| NNS
and  ||| S:373 E:377 ||| CC
50 ||| S:377 E:379 ||| CD
%  ||| S:379 E:381 ||| NN
of  ||| S:381 E:384 ||| IN
children  ||| S:384 E:393 ||| NNS
after  ||| S:393 E:399 ||| IN
LVAD  ||| S:399 E:404 ||| NNP
placement ||| S:404 E:413 ||| NN
.  ||| S:413 E:415 ||| .
LVAD  ||| S:415 E:420 ||| NNP
thrombosis  ||| S:420 E:431 ||| NN
and  ||| S:431 E:435 ||| CC
embolic  ||| S:435 E:443 ||| JJ
stroke  ||| S:443 E:450 ||| NN
lead  ||| S:450 E:455 ||| NN
to  ||| S:455 E:458 ||| TO
significant  ||| S:458 E:470 ||| JJ
long-term  ||| S:470 E:480 ||| JJ
morbidity ||| S:480 E:489 ||| NN
.  ||| S:489 E:491 ||| .
Adults  ||| S:491 E:498 ||| NNS
are  ||| S:498 E:502 ||| VBP
treated  ||| S:502 E:510 ||| VBN
with  ||| S:510 E:515 ||| IN
antithrombotic  ||| S:515 E:530 ||| JJ
therapy  ||| S:530 E:538 ||| NN
to  ||| S:538 E:541 ||| TO
prevent  ||| S:541 E:549 ||| VB
thrombotic  ||| S:549 E:560 ||| JJ
complications ||| S:560 E:573 ||| NNS
,  ||| S:573 E:575 ||| ,
but  ||| S:575 E:579 ||| CC
the  ||| S:579 E:583 ||| DT
amount  ||| S:583 E:590 ||| NN
and  ||| S:590 E:594 ||| CC
intensity  ||| S:594 E:604 ||| NN
of  ||| S:604 E:607 ||| IN
treatment  ||| S:607 E:617 ||| NN
differs  ||| S:617 E:625 ||| VBZ
between  ||| S:625 E:633 ||| IN
institutions ||| S:633 E:645 ||| NNS
.  ||| S:645 E:647 ||| .
The  ||| S:647 E:651 ||| DT
goal  ||| S:651 E:656 ||| NN
international  ||| S:656 E:670 ||| JJ
normalized  ||| S:670 E:681 ||| JJ
ratio  ||| S:681 E:687 ||| NN
for  ||| S:687 E:691 ||| IN
warfarin  ||| S:691 E:700 ||| JJ
therapy  ||| S:700 E:708 ||| NN
varies  ||| S:708 E:715 ||| VBZ
from  ||| S:715 E:720 ||| IN
1.5  ||| S:720 E:724 ||| CD
to  ||| S:724 E:727 ||| TO
3.0 ||| S:727 E:730 ||| CD
.  ||| S:730 E:732 ||| .
Some  ||| S:732 E:737 ||| DT
physicians  ||| S:737 E:748 ||| NNS
manage  ||| S:748 E:755 ||| VBP
adult  ||| S:755 E:761 ||| JJ
LVAD  ||| S:761 E:766 ||| NN
patients  ||| S:766 E:775 ||| NNS
without  ||| S:775 E:783 ||| IN
antiplatelet  ||| S:783 E:796 ||| JJ
medication ||| S:796 E:806 ||| NN
,  ||| S:806 E:808 ||| ,
whereas  ||| S:808 E:816 ||| IN
other  ||| S:816 E:822 ||| JJ
adults  ||| S:822 E:829 ||| NNS
are  ||| S:829 E:833 ||| VBP
treated  ||| S:833 E:841 ||| VBN
with  ||| S:841 E:846 ||| IN
aspirin  ||| S:846 E:854 ||| NN
as  ||| S:854 E:857 ||| IN
a  ||| S:857 E:859 ||| DT
single  ||| S:859 E:866 ||| JJ
agent  ||| S:866 E:872 ||| NN
or  ||| S:872 E:875 ||| CC
combined  ||| S:875 E:884 ||| VBN
with  ||| S:884 E:889 ||| IN
dipyridamole ||| S:889 E:901 ||| NN
.  ||| S:901 E:903 ||| .
In  ||| S:903 E:906 ||| IN
contrast ||| S:906 E:914 ||| NN
,  ||| S:914 E:916 ||| ,
physicians  ||| S:916 E:927 ||| NNS
typically  ||| S:927 E:937 ||| RB
manage  ||| S:937 E:944 ||| VB
children  ||| S:944 E:953 ||| NNS
with  ||| S:953 E:958 ||| IN
LVADs  ||| S:958 E:964 ||| JJ
using  ||| S:964 E:970 ||| VBG
the  ||| S:970 E:974 ||| DT
Edmonton  ||| S:974 E:983 ||| NNP
Anticoagulation  ||| S:983 E:999 ||| NNP
and  ||| S:999 E:1003 ||| CC
Platelet  ||| S:1003 E:1012 ||| NNP
Inhibition  ||| S:1012 E:1023 ||| NNP
Protocol ||| S:1023 E:1031 ||| NNP
,  ||| S:1031 E:1033 ||| ,
a  ||| S:1033 E:1035 ||| DT
detailed  ||| S:1035 E:1044 ||| JJ
algorithm  ||| S:1044 E:1054 ||| NN
for  ||| S:1054 E:1058 ||| IN
anticoagulation  ||| S:1058 E:1074 ||| NN
and  ||| S:1074 E:1078 ||| CC
antiplatelet  ||| S:1078 E:1091 ||| JJ
treatment  ||| S:1091 E:1101 ||| NN
modified  ||| S:1101 E:1110 ||| VBN
based  ||| S:1110 E:1116 ||| VBN
on  ||| S:1116 E:1119 ||| IN
thromboelastography  ||| S:1119 E:1139 ||| JJ
results ||| S:1139 E:1146 ||| NNS
.  ||| S:1146 E:1148 ||| .
LVAD  ||| S:1148 E:1153 ||| NNP
implantation  ||| S:1153 E:1166 ||| NN
causes  ||| S:1166 E:1173 ||| VBZ
consumption  ||| S:1173 E:1185 ||| NN
of  ||| S:1185 E:1188 ||| IN
coagulation  ||| S:1188 E:1200 ||| JJ
proteins ||| S:1200 E:1208 ||| NNS
,  ||| S:1208 E:1210 ||| ,
activation  ||| S:1210 E:1221 ||| VBG
of  ||| S:1221 E:1224 ||| IN
fibrinolysis ||| S:1224 E:1236 ||| NN
,  ||| S:1236 E:1238 ||| ,
and  ||| S:1238 E:1242 ||| CC
loss  ||| S:1242 E:1247 ||| NN
of  ||| S:1247 E:1250 ||| IN
high  ||| S:1250 E:1255 ||| JJ
molecular  ||| S:1255 E:1265 ||| JJ
weight  ||| S:1265 E:1272 ||| NN
von  ||| S:1272 E:1276 ||| NNP
Willebrand  ||| S:1276 E:1287 ||| NNP
protein  ||| S:1287 E:1295 ||| NN
multimers ||| S:1295 E:1304 ||| NN
.  ||| S:1304 E:1306 ||| .
How  ||| S:1306 E:1310 ||| WRB
these  ||| S:1310 E:1316 ||| DT
changes  ||| S:1316 E:1324 ||| NNS
in  ||| S:1324 E:1327 ||| IN
the  ||| S:1327 E:1331 ||| DT
coagulation  ||| S:1331 E:1343 ||| JJ
system  ||| S:1343 E:1350 ||| NN
influence  ||| S:1350 E:1360 ||| NN
the  ||| S:1360 E:1364 ||| DT
risk  ||| S:1364 E:1369 ||| NN
of  ||| S:1369 E:1372 ||| IN
hemorrhage  ||| S:1372 E:1383 ||| NN
and  ||| S:1383 E:1387 ||| CC
initiation  ||| S:1387 E:1398 ||| NN
of  ||| S:1398 E:1401 ||| IN
thrombosis  ||| S:1401 E:1412 ||| NN
is  ||| S:1412 E:1415 ||| VBZ
unknown ||| S:1415 E:1422 ||| JJ
.  ||| S:1422 E:1424 ||| .
Prospective ||| S:1424 E:1435 ||| JJ
,  ||| S:1435 E:1437 ||| ,
controlled  ||| S:1437 E:1448 ||| VBN
studies  ||| S:1448 E:1456 ||| NNS
are  ||| S:1456 E:1460 ||| VBP
needed  ||| S:1460 E:1467 ||| VBN
to  ||| S:1467 E:1470 ||| TO
determine  ||| S:1470 E:1480 ||| VB
the  ||| S:1480 E:1484 ||| DT
antithrombotic  ||| S:1484 E:1499 ||| JJ
regimen  ||| S:1499 E:1507 ||| NN
that  ||| S:1507 E:1512 ||| IN
most  ||| S:1512 E:1517 ||| RBS
effectively  ||| S:1517 E:1529 ||| RB
balances  ||| S:1529 E:1538 ||| JJ
bleeding  ||| S:1538 E:1547 ||| NN
and  ||| S:1547 E:1551 ||| CC
thrombosis  ||| S:1551 E:1562 ||| NN
in  ||| S:1562 E:1565 ||| IN
LVAD  ||| S:1565 E:1570 ||| NNP
patients ||| S:1570 E:1578 ||| NNS
.  ||| S:1578 E:1580 ||| .
